Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

China flag China · Delayed Price · Currency is CNY
63.76
-0.27 (-0.42%)
Apr 29, 2026, 3:00 PM CST
89.82%
Market Cap 11.16B
Revenue (ttm) 1.35B
Net Income (ttm) 274.30M
Shares Out 174.35M
EPS (ttm) 1.58
PE Ratio 40.51
Forward PE 36.80
Dividend 0.43 (0.65%)
Ex-Dividend Date Jun 11, 2025
Volume 1,466,330
Average Volume 3,993,175
Open 64.08
Previous Close 64.03
Day's Range 62.70 - 64.98
52-Week Range 32.55 - 80.48
Beta 0.14
RSI 46.56
Earnings Date Apr 22, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 1,522
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688513
Full Company Profile

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 284.06 million, an increase of 19.24%.

Financial Statements

News

There is no news available yet.